News
Issued by Hummingbird Bioscience, not Percheron Therapeutics Limited
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
June 25, 2025 · Published on GlobeNewswire
It isn’t one of Percheron Therapeutics Limited’s news releases, so 6ix doesn’t show it on Percheron Therapeutics Limited’s page or send it as an alert.